BioFire
BioMérieux Respiratory/Sore Throat Mini Panel Gets FDA Special 510(k) Clearance, CLIA Waiver
The firm said that it expects its SpotFire Respiratory/Sore Throat (R/ST) Panel Mini test to be available in the US in the third quarter of 2024.
ESCMID Global Panelists Underscore Role of Rapid Dx Testing in Antimicrobial Resistance Battle
Premium
In a BioMérieux-sponsored symposium, economist Lord Jim O'Neill revisited a 2016 report on AMR while experts discussed the use of rapid testing tools such as those offered by the French company.
BioMérieux Q3 Revenues Dip Slightly
The firm confirmed its full-year guidance for organic sales growth of between 4 percent and 6 percent.
BioMérieux Gets CLIA Waiver for BioFire SpotFire Respiratory Panel Mini
The CLIA waiver now allows the SpotFire system and two existing panels to be used by non-lab professionals at the point of care, the firm said.
BioMérieux Q1 Revenues Rise 8 Percent
The firm saw revenue growth across almost all business divisions, with a 32 percent jump in BioFire portfolio sales.
Feb 16, 2023
Jan 28, 2022
Sep 1, 2021
BioMérieux H1 Revenues Rise 7 Percent
Aug 31, 2021
Nov 6, 2020
Oct 22, 2020